

Azure Health Technology Limited trading as VGI Health Technology approved to list on National Stock Exchange

Sydney New South Wales, 19 May 2021 – The Directors are pleased to announce that Azure Health Technology Limited trading as VGI Health Technology (the **Company** or **VTL**) has been advised by the National Stock Exchange (NSX) that its Listing Application has been approved and the Company's shares are expected to commence trading on Friday 28 May 2021 under the ticker code NSX:VTL.

The CEO and Managing Director of VTL, Dr Glenn Tong, said "The successful completion of our IPO and now the imminent listing of our shares on the NSX is a major milestone for the Company and we are looking forward to many more value-adding milestones to be achieved in the near future. Our immediate focus is the launch of our nutraceutical products in the US and the advancement of our clinical development program for Non-Alcoholic SteatoHepatitis (NASH) and Pancreatic Adenocarcinoma (pancreatic cancer)."

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations
Ph:+61 (0) 419 788 431

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public biotechnology company which will list on the National Stock Exchange on 28 May 2021. AZT is developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.azureht.com.au>